WESTBROOK, Maine– IDEXX Laboratories, a global leader in veterinary diagnostics, has announced the release of its Catalyst® Cortisol Test, a new in-house diagnostic tool designed to help veterinarians quickly and accurately evaluate dogs for Addison’s disease and Cushing’s syndrome. The test marks the third expansion of the Catalyst diagnostic platform in less than a year, reflecting IDEXX’s commitment to advancing point-of-care veterinary care.
Addison’s disease, caused by insufficient cortisol production, is notoriously difficult to diagnose due to its vague symptoms that mimic other conditions. Cushing’s syndrome, which results from excessive cortisol, is more common in older dogs and certain breeds, and requires ongoing management to preserve quality of life. Both conditions benefit from early detection and tailored treatment—needs the new Catalyst Cortisol Test aims to address.
The test delivers quantitative cortisol results during the patient visit, allowing veterinarians to make immediate treatment decisions or adjust ongoing care plans. It also integrates with IDEXX VetLab® Station and VetConnect® PLUS, providing automated, real-time interpretation of results to support fast, informed clinical decisions.
“The Catalyst Cortisol Test addresses a critical need for veterinarians and supports improved health outcomes for dogs,” said Jay Mazelsky, President and CEO of IDEXX. “This latest expansion of the Catalyst platform exemplifies our ongoing promise to deliver technology that evolves with our customers’ needs and enhances care delivery.”
In addition to diagnostic accuracy, the test’s load-and-go functionality allows it to run alone or alongside other chemistry panels using a single sample, helping veterinary teams work more efficiently without sacrificing diagnostic depth. The design supports busy practices by reducing hands-on time and streamlining workflows.
Veterinary endocrinologist Dr. Patty Lathan emphasized the impact of in-clinic access to cortisol testing. “A reliable in-house test is game-changing—it enables faster diagnosis and treatment of a life-threatening Addisonian crisis in dogs and supports timely care for patients with Cushing’s syndrome.”
The Catalyst Cortisol Test will be available in the U.S. and Canada by the end of July, with global availability to more than 75,000 Catalyst chemistry analyzer users expected to follow in the third quarter of 2025.
